215 related articles for article (PubMed ID: 14614009)
21. Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer.
Brown RS; Edwards J; Dogan A; Payne H; Harland SJ; Bartlett JM; Masters JR
J Pathol; 2002 Oct; 198(2):237-44. PubMed ID: 12237884
[TBL] [Abstract][Full Text] [Related]
22. Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy.
Haram KM; Peltier HJ; Lu B; Bhasin M; Otu HH; Choy B; Regan M; Libermann TA; Latham GJ; Sanda MG; Arredouani MS
Prostate; 2008 Oct; 68(14):1517-30. PubMed ID: 18668517
[TBL] [Abstract][Full Text] [Related]
23. Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification.
Kim YH; Girard L; Giacomini CP; Wang P; Hernandez-Boussard T; Tibshirani R; Minna JD; Pollack JR
Oncogene; 2006 Jan; 25(1):130-8. PubMed ID: 16116477
[TBL] [Abstract][Full Text] [Related]
24. Alterations of androgen receptor in prostate cancer.
Linja MJ; Visakorpi T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):255-64. PubMed ID: 15663988
[TBL] [Abstract][Full Text] [Related]
25. Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival.
Murphy AJ; Hughes CA; Barrett C; Magee H; Loftus B; O'Leary JJ; Sheils O
Cancer Res; 2007 Mar; 67(6):2893-8. PubMed ID: 17363613
[TBL] [Abstract][Full Text] [Related]
26. Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line.
Watson PA; Ellwood-Yen K; King JC; Wongvipat J; Lebeau MM; Sawyers CL
Cancer Res; 2005 Dec; 65(24):11565-71. PubMed ID: 16357166
[TBL] [Abstract][Full Text] [Related]
27. Survivin mediates resistance to antiandrogen therapy in prostate cancer.
Zhang M; Latham DE; Delaney MA; Chakravarti A
Oncogene; 2005 Apr; 24(15):2474-82. PubMed ID: 15735703
[TBL] [Abstract][Full Text] [Related]
28. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays.
Bubendorf L; Kononen J; Koivisto P; Schraml P; Moch H; Gasser TC; Willi N; Mihatsch MJ; Sauter G; Kallioniemi OP
Cancer Res; 1999 Feb; 59(4):803-6. PubMed ID: 10029066
[TBL] [Abstract][Full Text] [Related]
29. Androgen axis in prostate cancer.
Culig Z; Bartsch G
J Cell Biochem; 2006 Oct; 99(2):373-81. PubMed ID: 16598769
[TBL] [Abstract][Full Text] [Related]
30. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
Vis AN; Schröder FH
BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
[TBL] [Abstract][Full Text] [Related]
31. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.
Berenguer C; Boudouresque F; Dussert C; Daniel L; Muracciole X; Grino M; Rossi D; Mabrouk K; Figarella-Branger D; Martin PM; Ouafik L
Oncogene; 2008 Jan; 27(4):506-18. PubMed ID: 17637748
[TBL] [Abstract][Full Text] [Related]
32. Modulation of mitogen-activated protein kinase cascades by differentiation-1 protein: acquired drug resistance of hormone independent prostate cancer cells.
Lin JC; Chang SY; Hsieh DS; Lee CF; Yu DS
J Urol; 2005 Nov; 174(5):2022-6. PubMed ID: 16217386
[TBL] [Abstract][Full Text] [Related]
33. Regulation of IkappaB kinase epsilon expression by the androgen receptor and the nuclear factor-kappaB transcription factor in prostate cancer.
Péant B; Diallo JS; Lessard L; Delvoye N; Le Page C; Saad F; Mes-Masson AM
Mol Cancer Res; 2007 Jan; 5(1):87-94. PubMed ID: 17259348
[TBL] [Abstract][Full Text] [Related]
34. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
Tepper CG; Vinall RL; Wee CB; Xue L; Shi XB; Burich R; Mack PC; de Vere White RW
Prostate; 2007 Apr; 67(5):521-35. PubMed ID: 17252539
[TBL] [Abstract][Full Text] [Related]
35. Overexpression and gene amplification of BAG-1L in hormone-refractory prostate cancer.
Mäki HE; Saramäki OR; Shatkina L; Martikainen PM; Tammela TL; van Weerden WM; Vessella RL; Cato AC; Visakorpi T
J Pathol; 2007 Aug; 212(4):395-401. PubMed ID: 17503439
[TBL] [Abstract][Full Text] [Related]
36. Genomic strategy for targeting therapy in castration-resistant prostate cancer.
Mendiratta P; Mostaghel E; Guinney J; Tewari AK; Porrello A; Barry WT; Nelson PS; Febbo PG
J Clin Oncol; 2009 Apr; 27(12):2022-9. PubMed ID: 19289629
[TBL] [Abstract][Full Text] [Related]
37. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations.
Shi Y; Chatterjee SJ; Brands FH; Shi SR; Pootrakul L; Taylor CR; Datar R; Cote RJ
BJU Int; 2006 Jan; 97(1):170-8. PubMed ID: 16336351
[TBL] [Abstract][Full Text] [Related]
38. [Mechanism of inhibiting the proliferation of prostate cancer by finasteride: a study using cDNA microarray].
Chen G; Geng J; Zhang YF
Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(21):1489-92. PubMed ID: 16061029
[TBL] [Abstract][Full Text] [Related]
39. Molecular regulation of androgen action in prostate cancer.
Dehm SM; Tindall DJ
J Cell Biochem; 2006 Oct; 99(2):333-44. PubMed ID: 16518832
[TBL] [Abstract][Full Text] [Related]
40. Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer.
Davis JN; Wojno KJ; Daignault S; Hofer MD; Kuefer R; Rubin MA; Day ML
Cancer Res; 2006 Dec; 66(24):11897-906. PubMed ID: 17178887
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
